Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Communications Biology|November 5, 2022
Discovery of small molecule agonists of the Relaxin Family Peptide Receptor 2Maria Esteban-Lopez, Kenneth J Wilson, Courtney Myhr, et al.Bioorganic & Medicinal Chemistry Letters|June 24, 2010
Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitorsKenneth J Wilson, Carl R Illig, Jinsheng Chen, et al.Journal of Medicinal Chemistry|November 2, 2011
Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)Carl R Illig, Carl L Manthey, Mark J Wall, et al.Bioorganic & Medicinal Chemistry Letters|October 22, 2013
Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitorsCarl R Illig, Carl L Manthey, Sanath K Meegalla, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 17, 2019
Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosisElena M Kaftanovskaya, Hooi Hooi Ng, Mariluz Soula, et al.Bioorganic & Medicinal Chemistry Letters|January 30, 2002
Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitorsM Jonathan Rudolph, Carl R Illig, Nalin L Subasinghe, et al.Bioorganic & Medicinal Chemistry Letters|February 22, 2008
Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitorsMark J Wall, Jinsheng Chen, Sanath Meegalla, et al.Journal of Medicinal Chemistry|February 19, 2026
Structure-Activity Relationship Studies toward the Optimization of First-In-Class Selective Small Molecule Agonists of the GPCR Relaxin/Insulin-like Family Peptide Receptor 2Kenneth J Wilson, Maria Esteban-Lopez, Courtney Myhr, et al.Molecular Cancer Therapeutics|November 6, 2009
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemiaCarl L Manthey, Dana L Johnson, Carl R Illig, et al.Pageof 2